| Basics |
Spero Therapeutics, Inc.
Spero Therapeutics Inc is a multi asset clinical stage biopharmaceutical company. It is focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections.
|
| IPO Date: |
November 2, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$127.33M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.24 | 3.06%
|
| Avg Daily Range (30 D): |
$0.06 | 2.59%
|
| Avg Daily Range (90 D): |
$0.06 | 2.58%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.52M |
| Avg Daily Volume (30 D): |
.44M |
| Avg Daily Volume (90 D): |
.56M |
| Trade Size |
| Avg Trade Size (Sh.): |
223 |
| Avg Trade Size (Sh.) (30 D): |
195 |
| Avg Trade Size (Sh.) (90 D): |
194 |
| Institutional Trades |
| Total Inst.Trades: |
96 |
| Avg Inst. Trade: |
$1.7M |
| Avg Inst. Trade (30 D): |
$1.83M |
| Avg Inst. Trade (90 D): |
$1.18M |
| Avg Inst. Trade Volume: |
.19M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.03M |
| Avg Closing Trade (30 D): |
$1.11M |
| Avg Closing Trade (90 D): |
$1.11M |
| Avg Closing Volume: |
300.61K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-.79
|
$-.13
|
$-.03
|
|
Diluted EPS
|
$-.79
|
$-.13
|
$-.03
|
|
Revenue
|
$ 40.55M
|
$ 5.44M
|
$ 14.19M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -43.84M
|
$ -7.38M
|
$ -1.7M
|
|
Operating Income / Loss
|
$ -46.82M
|
$ -7.92M
|
$ -2.44M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -27.67M
|
$ 17.42M
|
$ -17.69M
|
|
PE Ratio
|
|
|
|
|
|
|
